Role of Aromatic Amine Acetyltransferases, NAT1 and NAT2, in Carcinogen-DNA Adduct Formation in the Human Urinary Bladder

Cancer Research

Volumn 55, Issue 22, 1995, Pages 5230-5237

  Kadlubar, Fred F ^a   Hirvonen, Ari ^b   Bell, Douglas A ^b   Lang, Nicholas P ^c   Badawi, Alaa F ^d  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; ACYLTRANSFERASE;

ARTICLE; BLADDER CARCINOGENESIS; CARCINOGEN DNA INTERACTION; CYTOSOL; DNA ADDUCT; DNA POLYMORPHISM; DRUG ACETYLATION; DRUG ACTIVITY; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; PHENOTYPE; POLYADENYLATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

4-AMINOBENZOIC ACID; ACETYLATION; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; BLADDER; CARCINOGENS; DNA ADDUCTS; HUMAN; MOLECULAR SEQUENCE DATA; SMOKING; SULFAMETHAZINE;

EID: 0028879678     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Doll, R., and Peto, R. The causes of cancer. J. Natl. Cancer Inst., 66:1191–1308, 1981.
2. Beland, F. A., and Kadlubar, F. F. Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons. In:C. S. Cooper and P. L. Grover (eds.), Chemical Carcinogenesis and Mutagenesis, Vol. I, pp. 267–325. Berlin:Springer-Verlag, 1990.
3. Kadlubar, F. F. DNA adducts of carcinogenic aromatic amines. In:K. Hemminki, A. Dipple, D. E. G. Shuker, F. F. Kadlubar, D. Segerback, and H. Bartsch (eds.), DNA adducts, Identification and Biological Significance, IARC Scientific Publication No. 125, pp. 199–216. Lyon:IARC, 1994.
4. Kadlubar, F. F., Talaska, G., Lang, N. P., Benson, R. W., and Roberts, D. W. Assessment of exposure and susceptibility to aromatic amine carcinogens. In:H. Bartsch, K. Hemminki, and I. K. O'Neill (eds.), Methods for Detecting DNA Damaging Agents in Humans:Applications in Cancer Epidemiology and Prevention, IARC Scientific Publication No. 89, pp. 174–199. Lyon:IARC, 1988.
5. Kadlubar, F. F. Carcinogenic aromatic amine metabolism and DNA adduct detection in human. In:L. Ernster (ed.), Xenobiotics and Cancer, pp. 329–338. London:Taylor & Francis, Ltd., 1991.
6. Dipple, A. DNA adducts of chemical carcinogens. Carcinogenesis (Lond.), 16:437–441, 1995.
7. Miller, E. C., and Miller, J. A. Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer (Phila.), 47:2327–2345, 1981.
8. Gelboin, H. V. Benzo(a)pyrene metabolism, activation and carcinogenesis:role and regulation of mixed-function oxidases and related enzymes. Physiol. Rev., 60:1107–1166, 1980.
9. Saffhill, R., Margison, G. P., and O'Connor, P. J. Mechanisms of carcinogenesis induced by alkylating agents. Biochem. Biophys. Acta, 823:111–145, 1985.
10. Badawi, A. F., and Mostafa, M. H. Possible mechanisms of alteration in the capacities of carcinogen metabolizing enzymes during schistosomiasis and their role in bladder cancer induction. J. Int. Med. Res., 21:281–305, 1993.
11. Gelboin, H. V. Carcinogen, drugs, and cytochrome P-450. N. Engl. J. Med., 309:105–107, 1983.
12. Conney, A. H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons:G. H. A. Clowes Memorial Lecture. Cancer Res., 42:4875–4917, 1982.
13. Kadlubar, F. F. Biochemical individuality and its implications for drug and carcinogen metabolism:recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metabol. Rev., 26:37–46, 1994.
14. Weber, W. W. The acetylator genes and drug response. New York:Oxford University Press, 1987.
15. Miles, J. S., and Wolf, C. R. Developments and prespectives on the role of cytochrome P450s in chemical carcinogenesis. Carcinogenesis (Lond.), 12:2195–2199, 1991.
16. Kadlubar, F. F., Butler, M. A., Kaderlik, K. R., Chou, H-C, and Lang, N. P. Polymorphisms of aromatic amine metabolism in humans:relevance for human carcinogenesis. Environ. Health Persp., 98:69–74, 1992.
17. Bartsch, H., Malaveille, C, Friesen, M., Kadlubar, F. F., and Vineis, P. Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV. Molecular dosimetry studies implicates aromatic amines as bladder carcinogens. Eur. J. Cancer, 8:1199–1207, 1993.
18. Kirlin, W. G., Trinidad, A., Yerokun, T., Ogolla, F., Ferguson, R. J., Andrews, A. F., Brady, P. K., and Hein, D. W. Polymorphic expression of acetyl coenzyme A-de-pendent 0-acetyltransferase-mediated activation of JV-hydroxyarylarnines by human bladder cytosols. Cancer Res., 49:2448–2454, 1989.
19. Frederickson, S. M., Messing, E. M., Reznikoff, C. A., and Swaminathan, S. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyl transferase and O-acetyltransferase activities in human urothelial cells. Cancer Epidemiol., Biomar-kers & Prev., 3:25–32, 1994.
20. Kaderlik, K. R., and Kadlubar, F. F. Metabolic polymorphisms and carcinogen DNA-adduct formation in human populations. Pharmacogenetics, in press, 1995.
21. Wild, D., Feser, W., Michel, S., Lord, H. L., and Josephy, P. D. Metabolic activation of heterocyclic aromatic amines by human arylamine/V-acetyltransferase isoenzymes (NAT1 and NAT2) expressed in Salmonella tvphimurium. Carcinogenesis (Lond.), 16:643–648, 1995.
22. Badawi, A. F., Stern, S. J., Lang, N. P., and Kadlubar, F. F. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. In:C. L. Walker and J. D. Groopman (eds.), Carcinogenesis and Risk Assessment:Genetics and Susceptibility–Impact on Risk Assessment, in press. New York:John Wiley & Sons, 1995.
23. Hemminki, K. Exposure to chemical carcinogens. In:C. S. Cooper and P. L. Grover (eds.), Chemical Carcinogenesis and Mutagenesis, Vol. I, pp. 33–62. Berlin:Springer-Verlag, 1990.
24. Lin, H. J., Han, C.-Y., Lin, B. K., and Hardy, S. Ethnic distribution of slow acetylator mutations in the polymorphic W-acety I transferase (NAT2) gene. Pharmacogenetics, 4:125–134, 1994.
25. Vineis, P. Epidemiological models of carcinogenesis:the example of bladder cancer. Cancer Epidemiol., Biomarkers & Prev., 1:149–53, 1992.
26. Vineis, P., Caporaso, N., Tannenbaum, S. R., Skipper, P. L., Glogowski, J., Bartsch, H., Coda, M., Talaska, G., and Kadlubar, F. F. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking. Cancer Res., 50:3002–3004, 1990.
27. Vineis, P., Bartsch, H., Caporaso, N., Harrington, A. M., Kadlubar, F. F., Landi, M. T. Malaveille, C, Shields, P. G., Skipper, P., Talaska, G., and Tannenbaum, S. R. Genetically based JV-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature (Lond.), 369:154–156, 1994.
28. Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., and Kadlubar, F. F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 2:116–127, 1992.
29. Butler, M. A., Iwasaki, M., Guengerich, F. P., and Kadlubar, F. F. Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA, 86:7696–7700, 1989.
30. Weber, W. W., and Vatsis, K. P. Individual variability in p-aminobenzoic acid W-acetylation by human acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics, 3:209–212, 1993.
31. Vatsis, K. P., and Weber, W. W. Structural heterogenicity of Caucasian N-acetyl-transferase at the NAT1 gene locus. Arch. Biochem. Biophys., 301:71–76, 1993.
32. Bell, D. A., Badawi, A. F., Lang, N. P., Ilett, K. F., Kadlubar, F. F., and Hirvonen, A. Polymorphism in the W-acety(transferase 1 (NAT1) polyadenylation signal:association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res., 55:5226–5229, 1995.
33. Kirby, K. S., and Cook, E. A. A new method for the isolation of deoxyribonucleic acid. Biochem. J., 66:459–504, 1957.
34. Badawi, A. F., Mostafa, M. H., Aboul-Azm, T., Haboubi, N. Y., O'Connor, P. J., and Cooper, D. P. Promutagenic methylation damage in bladder DNA from patients with bladder cancer associated with schistosomiasis and from normal individuals. Carcinogenesis (Lond.), 13:877–881, 1992.
35. Laberca, C., and Paigen, K. A simple and sensitive DNA assay procedure. Anal. Biochem., 102:344–352, 1980.
36. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72:248–254, 1976.
37. Ilett, K. F., Reeves, P. T., Minchin, R. F., Kinnear, R. E., Watson, H. F., and Kadlubar, F. F. Distribution of acetyl transferase activities in the intestines of rapid and slow acetylator rabbits. Carcinogenesis (Lond.), 12:1465–1469, 1991.
38. Reeves, P. T., Minchin, R. F., and Ilett, K. F. Induction of sulfamethazine acetylation by hydrocortisone in the rabbit. Drug Metabol. Disp., 16:110–116, 1988.
39. Ilett, K. F., Ingram, D. M., Carpenter, D. S., Teitel, C. H., Lang, N. P., Kadlubar, F. F., and Minchin, R. F. Expression of monomorphic and polymorphic N-acetyltrans-ferases in human colon. Biochem. Pharmacol., 47:914–917, 1994.
40. Flammang, T. J., and Kadlubar, F. F. Acetyl coenzyme A-dependent metabolic activation of yV-hydroxy-3,2'-dimethyl-4-aminobiphenyl and several carcinogenic W-hydroxy arylamines in relation to tissue and species differences, other acyl donors, and arylhydroxamic acid-dependent acetyltransferases. Carcinogenesis (Lond.), 7; 919–926, 1986.
41. Vatsis, K. P., Weber, W., Bell, D. A., Dupret, J.-M., Evans, D. A. P., Grant, D. M., Hein, D. W., Lin, H. J., Meyer, U. A., Relling, M. V., Sim, E., Suzuki, T., and Yamazoe, Y. Nomenclature for N-acetyltransferases. Pharmacogenetics, 5:1–9, 1995.
42. Bell, D. A., Taylor, J. A., Butler, M. A., Stephans, E., Wiest, J., Brubaker, L., Kadlubar, F. F., and Lucier, G. W. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis (Lond.), 14:1689–1692, 1993.
43. Bell, D. A., Stephans, E. A., Castranio, T., Umbach, D. M., Watson, M. A., Deakin, M., Elder, J., Hendrickse, C., Duncan, H., and Strange, R. C. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res., 55:3537–3542, 1995.
44. Gupta, R. C., Reddy, M. V., and Randerath, K. 32P-Postlabelling analysis of nonradioactive aromatic carcinogen-DNA adducts. Carcinogenesis (Lond.), 3:1081–1092, 1982.
45. Gupta, R. C., and Earley, K. 32P-Adduct assay:comparative recoveries of structurally diverse DNA adducts in the various enhancement procedures. Carcinogenesis (Lond.), 9:1687–1693, 1988.
46. Talaska, G., Al-Juburi, A. Z. S. S., and Kadlubar, F. F. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder:identification of N-(de-oxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc. Natl. Acad. Sci. USA, 88:5350–5354, 1991.
47. Gupta, R. C. Enhanced sensitivity of 32P-postlabelling analysis of aromatic carcinogens:DNA adducts. Cancer Res., 45:5656–5662, 1985.
48. Kaderlik, K. R., Talaska, G., DeBord, D. G., Osorio, M., and Kadlubar, F. F. 4,4'-Methylenebis(2-chloroaniline)-DNA adduct analysis in human exfoliated urothelial cells by 32P-postlabelling. Cancer Epidemiol., Biomarkers & Prev., 2:63–69, 1993.
49. Shapiro, S. S., and Wilk, M. B. An analysis of variance test for normality (complete samples). Biometrika, 52:591–611, 1965.
50. Finney, D. J. Probit analysis. London:Cambridge University Press, 1964.
51. Minchin, R. F., Reeves, P. T., Teitel, C. H., McManus, M. E., Mojarrabi, B., Ilett, K. F., and Kadlubar, F. F. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in C0S-1 cells. Biochem. Biophys. Res. Commun., 185:839–844, 1992.
52. Swaminathan, S., and Reznikoff, C. A. Metabolism and nucleic acid binding of N-hydroxy-4-acetylaminobiphenyl and N-acetoxy-4-acetylaminobiphenyl by cultured human uroepithelial cells. Cancer Res., 52:3286–3294, 1992.
53. Kalow, W. Pharmacogenetics:heredity and the response to drugs. Philadelphia:W. B. Saunders, 1962.
54. Gonzalez, F. J., and Gelboin, H. V. Role of human cytochrome P-450s in risk assessment and susceptibility to environmentally based disease. J. Toxicol. Environ. Health, 40:289–308, 1993.
55. Kellermann, G., Shaw, C. R., and Luyten-Kellermann, M. Aryl-hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N. Engl. J. Med., 289:934–937, 1973.
56. Caporaso, N., Hayes, R. B., Dosemeci, M., Hoover, R., Ayesh, R., Hetzel, M., and Idle, J. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotypc. Cancer Res., 49:3675–3679, 1989.
57. Kihara, M., Kihara, M., and Noda, K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis (Lond.), 75:415–418, 1994.
58. Daly, A. K., Thomas, D. J., Cooper, J., Pearson, W. R., Neal, D. E., and Idle, J. R. Homozygous deletion of gene for glutathione 5-transferase Ml in bladder cancer. Br. Med. J., 307:481, 1993.
59. Bell, D. A., Taylor, J. A., Paulson, D., Robertson, D., Mohler, J., and Lucier, G. W. Genetic risk and carcinogen exposure:a common inherited defect of the carcinogen metabolism gene glutathione transferase Ml (GSTM1) is associated with increased susceptibility to bladder cancer. J. Natl. Cancer Inst., 85:1159–1164, 1993.
60. Lin, H. J., Han, C.-Y., Bernstein, D. A., Hsiao, W., Lin, B. K., and Hardy, S. Ethnic distribution of the glutathione transferase Mu 1–1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis (Lond.), 15:1077–1081, 1994.
61. Singhal, S. S., Saxena, M., Awasthi, S., Ahmed, H., Sharma, R., and Awasthi, Y. C. Gender related differences in expression and characteristics of glutathione 5-trans-ferases of human colon. Biochem. Biophys. Acta, 1171:19–26, 1992.
62. Zhong, S., Wyille, A. H., Barnes, D., Wolf, C. R., and Spurr, N. K. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast, and colon cancer. Carcinogenesis (Lond.), 14:1821–1824, 1993.
63. Talaska, G., Schamer, M., Skipper, P., Tannenbaum, S., Caporaso, N., Kadlubar, F. F., Bartsch, H., and Vineis, P. Carcinogen-DNA adducts in exfoliated urothelial cells:techniques for noninvasive human monitoring. Environ. Health Persp., 99:289–291, 1993.
64. Fredrickson, S. M., Hatcher, J. F., Reznikoff, C. A., and Swaminathan, S. Acetyl transferase-mediated metabolic activation of yV-hydroxy-4-aminobiphenyl by human uroepithelial cells. Carcinogenesis (Lond.), 13:955–961, 1992.
65. Reznikoff, C. A., Kao, C, Messing, E. M., Newton, M., and Swaminathan, S. A molecular genetic model of human bladder carcinogenesis. Semin. Cancer Biol., 4:143–152, 1993.
66. Probst, M., Blum, M., Fasshauer, I., D'Orazio, D., Meyer, U., and Wild, D. The role of the human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-raethylimidazo[4,5-/]quinoline (IQ). Carcinogenesis (Lond.), 13:1713–1717, 1992.
67. Talaska, G., Schamer, M., Skipper, P., Tannenbaum, S., Caporaso, N., Unruh, L., Kadlubar, F. F., Bartsch, H., Malaveille, C, and Vineis, P. Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers:association with smoking, hemoglobin adducts and urinary mutagenicity. Cancer Epidemiol., Biomarkers & Prev., 1:61–66, 1991.
68. Chou, H.-C., Lang, N. P., and Kadlubar, F. F. Metabolic activation of the hydroxy derivative of the carcinogen 4-aminobiphenyI by human sulfotransferase. Carcinogenesis (Lond.), 16:413–417, 1995.
69. Flammang, T. J., Yamazoe, Y., Guengerich, F. P., and Kadlubar, F. F. The S-acetyl coenzyme A-dependent metabolic activation of the carcinogen AMiydroxy-2-amin-ofluorene and its relationship to the aromatic amine acetyltransferase phenotype. Carcinogenesis (Lond.), 8:1967–1970, 1987.
70. Flammang, T. J., Hein, D. W., Talaska, G., and Kadlubar, F. F. Af-Hydroxyarylamine 0-acetyltransferase and its relationship to aromatic amine ZV-acetyltransferase polymorphism in the inbred hamster and in human tissue cytosol. In:C. King, D. Schuetzle, and L. Romano (eds.), Carcinogenesis and Mutagenesis Responses to Aromatic Amines and Nitroarenes, pp. 137–148. New York:Elsevier Publishing Co., 1988.
71. Cartwright, R. A., Glashan, R. W., Rogers, J. J., Barham-Hall, D., Ahmed, R. A., Higgins, E., and Kahan, M. A. The role of N-acetyltransferase in bladder carcinogenesis:a pharmacogenetic epidemiological approach to bladder cancer. Lancet, 2:842–845, 1982.
72. Mommsen, S., and Aagaard, J. Susceptibility in urinary bladder cancer:acetyltransferase phenotypes and related risk factors. Cancer Lett., 32:199–205, 1986.
73. Caporaso, N., Landi, M. T., and Vineis, P. Relevance of metabolic polymorphisms to human carcinogenesis:evaluation of epidemiologic evidence. Pharmacogenetics, 1:4–19, 1991.
74. Taylor, J. A., Umbach E., Stephans, E., Paulson, D., Robertson, C, Mohler, J. L., and Bell, D. A. The role of AT-acetylation polymorphisms at NAT1 and NAT2 in smoking-associated bladder cancer. Proc. Am. Assoc. Cancer Res., 36:1681, 1995.